Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Withdrawn 1Unknown 1Completed 1

Sponsor Class

OTHER_GOV 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1

Conditions

Leukemia, Myeloid, Acute 1

Interventions

Cytarabine 465Cyclophosphamide 459fludarabine phosphate 277Rituximab 249Methotrexate 245Etoposide 203fludarabine 200Filgrastim 199Peripheral Blood Stem Cell Transplantation 180Busulfan 169Vincristine 163Dexamethasone 153Daunorubicin 151Azacitidine 145Mycophenolic Acid 142Whole-Body Irradiation 133Tacrolimus 127Imatinib Mesylate 127Cyclosporine 123Granulocyte Colony-Stimulating Factor 118Radiotherapy 113Melphalan 110Idarubicin 103Doxorubicin 101Mitoxantrone 97Antilymphocyte Serum 97Lenalidomide 96Decitabine 96Mercaptopurine 93Prednisone 91

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × bisantrene × Other hematologic neoplasm × Clear all
NCT03820908 2020-08-07

Bisantrene for Relapsed /Refractory AML

Sheba Medical Center

Phase 2 Completed
10 enrolled
Other hematologic neoplasm

Leukemia, Myeloid, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡